<SEC-DOCUMENT>0001628280-24-047099.txt : 20241112
<SEC-HEADER>0001628280-24-047099.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112160118
ACCESSION NUMBER:		0001628280-24-047099
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241112
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		241447752

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94084

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sgmo-20241112.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c41ff5ca-2b50-4b76-8b33-b88e8ab04a52,g:83ec6252-6842-49ae-8980-2fdb865b3d01,d:b7188c371953431c9bb116502831021b-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20241112</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20241112.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-12</xbrli:startDate><xbrli:endDate>2024-11-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib7188c371953431c9bb116502831021b_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November&#160;12, 2024</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.574%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30171</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>ID Number)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">501 Canal Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Richmond</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94804</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">510</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">970-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:6.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"/><td style="width:6.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.681%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.574%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.01 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;12, 2024, Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;) issued a press release announcing its financial results for the quarter ended September 30, 2024 (the &#8220;Press Release&#8221;).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:12.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.165%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.901%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.693%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991111224.htm">Press Release regarding financial results dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991111224.htm">November 12</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-991111224.htm">, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.990%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 12, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT B. WILLOUGHBY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott B. Willoughby</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit-991111224.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia7ac7e5d1f684cf5a1e61f8a041c9e59_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:432pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="logoa.gif" src="logoa.gif" style="height:100px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THIRD QUARTER 2024 FINANCIAL RESULTS</font></div><div><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1&#47;2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer plans to present detailed data from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene therapy that Sangamo has co-developed with and licensed to Pfizer, via a platform presentation at the 66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">American Society for Hematology (ASH) Annual Meeting and Exposition.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Received $50 million in upfront license fees and milestone payments in connection with previously announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases, and eligible to earn up to $1.9 billion in additional milestone payments, plus tiered royalties on net sales.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Submitted investigational new drug (IND) application to FDA for ST-503 for the treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RICHMOND, California, November 12, 2024 - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (Nasdaq&#58; SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;This is a pivotal time for Sangamo as we build upon our recent strong momentum with news of a clear regulatory pathway to Accelerated Approval in the U.S. for ST-920 in Fabry disease, accelerating time to potential approval by approximately three years,&#8221; said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. &#8220;Alongside Pfizer&#8217;s Hemophilia A program activities, and against a backdrop of our recent epigenetic regulation and capsid license agreement with Genentech, these developments create a strong foundation for our core neurology pipeline, which continues to advance. We were thrilled to submit our first neurology IND application this quarter for ST-503 for the treatment of intractable pain due to idiopathic small fiber neuropathy and expect to be in the clinic in mid-2025. We are proud of our scientific and strategic execution so far this year and are continuing to work diligently to secure additional funding to further advance our wholly owned neurology programs, capsid delivery technology and next-generation genome engineering capabilities.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Highlights</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Updates</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced in August a global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Received $50.0 million from Genentech in upfront license fees and milestone payments.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Eligible to earn up to $1.9 billion from Genentech in additional development and commercial milestones spread across multiple potential products under the agreement and tiered royalties on net sales of such products, subject to certain specified reductions.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fabry Disease</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced in October the outcome of a successful interaction with the FDA, providing a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec, or ST-920, an investigational gene therapy for the treatment of Fabry disease. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA has agreed in a Type B interaction that data from the ongoing Phase 1&#47;2 STAAR study can serve as the primary basis for approval under the Accelerated Approval Program, using estimated glomerular filtration rate (eGFR) slope as an intermediate clinical endpoint. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sangamo engaged with the FDA on alternative pathways to potential approval following analysis of clinical data from the Phase 1&#47;2 STAAR study showing encouraging safety and efficacy data, including promising preliminary evidence of improved kidney function. In the 18 male and female patients treated with isaralgagene civaparvovec with more than one year of follow-up data, a statistically significant positive mean annualized eGFR slope was observed.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on these latest data, the FDA agreed that eGFR slope at 52 weeks can serve as an intermediate clinical endpoint to support a potential Accelerated Approval. The FDA also advised that eGFR slope at 104 weeks may be assessed to verify clinical benefit.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The complete dataset to support an Accelerated Approval pathway will be available in the first half of 2025. This approach unlocks a potential Biologics License Application (BLA) submission in the second half of 2025, three years ahead of previous estimates, and avoids the requirement for an additional, costly registrational study to establish clinical efficacy.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dosing was completed in the Phase 1&#47;2 STAAR study in April 2024, with a total of 33 patients dosed. The longest treated patient recently achieved four years of follow-up. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The 18th and final patient who started the study on Enzyme Replacement Therapy (ERT), was successfully withdrawn from ERT in September 2024, and all 18 patients remain off ERT as of today.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sangamo has begun to execute BLA readiness activities for isaralgagene civaparvovec, while continuing to advance ongoing business development discussions with potential collaboration partners.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia A</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pfizer will be presenting detailed data from the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy that Sangamo has co-developed with and licensed to Pfizer for the treatment of adults with moderately severe to severe hemophilia A, in an oral presentation at the 66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASH Annual Meeting and Exposition on December 9, 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ASH abstract confirmed that the AFFINE trial met its primary endpoint of non-inferiority and superiority, with a statistically significant decrease in total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment (mean total ABR estimates, 1.24 vs 4.73). </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Key secondary endpoints as defined by the trial protocol &#8211; the percentage of participants with FVIII activity &#62;5% (chromogenic assay) at 15 months and ABR for treated bleeds &#8211; were met, and also demonstrated superiority compared to prophylaxis. At Month 15, 84% of participants had FVIII activity &#62;5%, with 82.8% of participants continuing to maintain FVIII activity &#62;5% at 2-years post-infusion. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Treated ABR during Week 12 through &#8805;15 months post-infusion was significantly reduced compared to prophylaxis (mean treated ABR estimates, 0.07 vs. 4.08), demonstrating superiority.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the AFFINE trial, giroctocogene fitelparvovec was generally well tolerated with no study discontinuations.  </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pfizer is discussing these data with regulatory authorities.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sangamo is eligible to earn from Pfizer up to $220.0 million in milestone payments upon the achievement of certain regulatory and commercial milestones for giroctocogene fitelparvovec and product sales royalties of 14% - 20% if giroctocogene fitelparvovec is approved and commercialized, subject to certain reductions.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neurology Pipeline</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chronic Neuropathic Pain</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submitted IND application to the FDA for ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Assuming clearance of this IND by the FDA, we expect to start the Phase 1&#47;2 study in the middle of 2025.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Published a manuscript in bioRxiv titled, &#8220;Potent and selective repression of SCN9A by engineered zinc finger repressors (ZFRs) for the treatment of neuropathic pain&#8221; demonstrating that ZFRs can selectively and potently reduce the expression of Nav1.7 sodium channels in sensory neurons in animal models, following a single intrathecal administration of ST-503.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prion Disease</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial authorization (CTA) enabling activities continue to advance for Sangamo&#8217;s program to treat prion disease, leveraging our novel neurotropic AAV capsid known as STAC-BBB, that has demonstrated industry-leading blood brain barrier penetration in nonhuman primates (NHPs) following intravenous administration. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented updated data at Prion 2024 Conference in October 2024, showing the potency of Sangamo&#8217;s ZFR in a disease mouse model at multiple dose levels. The ZFR significantly reduced expression of prion mRNA and protein in the brain, extended mouse survival and limited the formation of toxic prion aggregates.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Additionally, we presented NHP data at the Prion 2024 Conference, showing that a single intravenous administration of the prion ZFR, delivered via STAC-BBB, resulted in potent and widespread repression of the prion gene in transduced neurons.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A CTA submission is expected in the fourth quarter of 2025. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novel Adeno-Associated Virus (AAV) Capsid Delivery Technology</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to engage in business development discussions with new potential collaborators for STAC-BBB for use in delivering intravenously administered genomic medicines for certain specified neurological diseases.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third Quarter 2024 Financial Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated net income available for common stockholders for the third quarter ended September 30, 2024 was $10.7 million, or $0.04 per share on a fully diluted basis, compared to a net loss of $104.2 million, or $0.59 per share, for the same period in 2023.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the third quarter ended September 30, 2024 were $49.4 million, compared to $9.4 million for the same period in 2023.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $40.0 million in revenues was primarily attributed to $49.2 million in revenue relating to our collaboration agreement with Genentech, Inc. This increase was partially offset by a decrease of $5.5 million in revenue relating to our collaboration agreement with Kite Pharma, Inc. which expired pursuant to its terms in April 2024, and a decrease of $3.7 million in revenue relating to our other license agreements.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAAP and Non-GAAP Operating Expenses</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.457%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.8&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.4&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and indefinite-lived intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.8&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.2&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386.2&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and indefinite-lived intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89.5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.3)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.2&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.3&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.7&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.0&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses on a GAAP basis for the third quarter ended September 30, 2024 were $38.8 million compared to $115.8 million for the same period in 2023. Non-GAAP operating expenses, which exclude impairment charges, depreciation and amortization and stock-based compensation expense as shown in the reconciliation table above, for the third quarter ended September 30, 2024 were $34.2 million, compared to $59.3 million for the same period in 2023.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in total operating expenses on a non-GAAP basis was primarily attributable to a decrease in preclinical and clinical expenses due to deferral and reprioritization of certain research and development programs, lower compensation and other personnel costs mainly due to lower headcount as a result of restructuring of operations and a corresponding reductions in </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">workforce announced during 2023, a decrease in external professional services costs, and a decrease in facilities and infrastructure related expenses. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents as of September 30, 2024 were $39.2 million, compared to cash, cash equivalents and marketable securities of $81.0 million as of December 31, 2023. We believe that our available cash and cash equivalents as of September&#160;30,&#160;2024, together with the $10.0 million milestone payment we received from Genentech, will be sufficient to fund our planned operations into the first quarter of 2025.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Guidance for 2024</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On a GAAP basis, we expect total operating expenses in the range of approximately $150 million to $170 million in 2024, which includes non-cash stock-based compensation expense, impairment expense, and depreciation and amortization.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $13 million, impairment expense of approximately $6 million, and depreciation and amortization of approximately $6 million, in the range of approximately $125 million to $145 million in 2024.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Upcoming Events</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo plans to participate in the following event&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jefferies London Healthcare Conference, November 19-21, 2024</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access links for available webcasts for investor conferences will be available on the Sangamo website in the Investors and Media section under </font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Available materials will be found on the Sangamo website after the event under </font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sangamo management team will hold a corporate call to further discuss program advancements and financial updates on Tuesday, November 12, at 4&#58;30pm Eastern Time.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants should register for, and access, the call using this</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> link</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. While not required, it is recommended you join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided or to use the dial-out option to connect their phone instantly.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An updated corporate presentation is available in the Investors and Media section under</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The link to access the live webcast can also be found on the Sangamo website in the Investors and Media section under</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A replay will be available following the conference call, accessible at the same link.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Sangamo Therapeutics</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo&#8217;s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> www.sangamo.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and connect with us on</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> LinkedIn </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</font><font style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Statements </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to&#58; the impact of business development and clinical advancements on Sangamo&#8217;s cash runway and ability to continue to operate as a going concern, the therapeutic and commercial potential of Sangamo&#8217;s product candidates, including the durability of therapeutic effects, the therapeutic and commercial potential of technologies used by Sangamo in its product candidates, including its gene therapy technologies and zinc finger platform, the potential of its adeno-associated virus capsid delivery platform, the potential for isaralgagene civaparvovec to qualify for the FDA&#8217;s Accelerated Approval program, including the adequacy of data generated in the Phase 1&#47;2 STAAR study to support any such approval&#59; expectations concerning the availability of additional data to support a potential BLA submission for isaralgagene civaparvovec, and the timing of such submission&#59; the potential to accelerate the expected timeline to approval&#59; the anticipated advancement of isaralgagene civaparvovec to registration, including Sangamo&#8217;s plans to seek a potential collaboration partner&#59; Sangamo&#8217;s ability to realize the expected benefits of the license agreement with Genentech, including </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">the potential for Sangamo to receive development and commercial milestone payments and royalties, Sangamo&#8217;s ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements, including its ability to find a collaboration partner for its Fabry disease program and additional collaborations with respect to Sangamo&#8217;s STAC-BBB capsid delivery platform and epigenetic regulation capabilities, and Pfizer&#8217;s continued advancements of the giroctocogene fitelparvovec program, including the potential for Pfizer to complete clinical development, regulatory interactions, manufacturing and global commercialization of any resulting products, anticipated revenues from existing and new collaborations and the timing thereof, the anticipated plans and timelines of Sangamo and its collaborators in conducting our ongoing and potential future clinical trials and presenting clinical data from such clinical trials, the anticipated advancement of Sangamo&#8217;s product candidates to late-stage development, advancement of Sangamo&#8217;s preclinical neurology programs, including announcement of such data, and anticipated CTA submission, Sangamo&#8217;s estimates regarding the sufficiency of its cash resources and its expenses, capital requirements and need for substantial additional financing, Sangamo&#8217;s 2024 financial guidance related to GAAP and non-GAAP total operating expenses, impairments and stock-based compensation, plans to participate in industry and investor conferences, Sangamo&#8217;s efforts and ability to secure additional funding, including plans to seek partners for certain of Sangamo&#8217;s programs and the discussions related thereto, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo&#8217;s lack of capital resources and need for substantial additional funding to execute its operating plan and to continue to operate as a going concern, including the risk that Sangamo will be unable to obtain funding or partnerships or additional collaboration partners necessary to advance its preclinical and clinical programs and to otherwise operate as a going concern, in which case Sangamo may be required to cease operations entirely, liquidate all or a portion of its assets and&#47;or seek protection under the U.S. Bankruptcy Code, the potential for Genentech to breach or terminate its agreement with Sangamo&#59; and the potential for Sangamo to fail to realize its expected benefits from the Genentech agreement, including but not limited to further validating the importance of the zinc finger platform to support the development of therapeutics for neurodegenerative diseases&#59; Sangamo&#8217;s ability to execute its restructurings as currently contemplated&#59; the uncertain and costly research and development process, including the risk that preclinical results may not be indicative of results in any future clinical trials&#59; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflicts, current or potential future bank failures, inflation and high interest rates, on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators, including the initiation and operation of clinical trials&#59; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates&#59; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1&#47;2 STAAR study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, including that the 52-week data from the Phase 1&#47;2 STAAR study will not support a BLA submission and&#47;or that the 104-week data from such study will not verify the clinical benefit of isaralgagene civaparvovec or support FDA approval, and that the patients withdrawn from ERT will remain off ERT&#59; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities&#59; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any registrational trial of Sangamo&#8217;s product candidates&#59; the potential for technological developments that obviate technologies used by Sangamo&#59; Sangamo&#8217;s reliance on collaborators and its potential inability to secure additional collaborations, and Sangamo&#8217;s ability to achieve expected future operating results.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All forward-looking statements about our future plans and expectations, including our financial guidance, are subject to our ability to secure adequate additional funding. There can be no assurance that Sangamo and its collaborators will be able to develop commercially viable products or that Sangamo will earn any milestone or royalty payments under its collaboration agreements. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and its collaborators. These risks and uncertainties are described more fully in Sangamo&#8217;s Securities and Exchange Commission, or SEC, filings and reports, including in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, as supplemented by Sangamo&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and subsequent filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measures</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP operating expenses, which excludes depreciation and amortization, stock-based compensation expense and impairment of goodwill, indefinite-lived intangible assets and long-lived assets from GAAP operating expenses. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare our results from period to period and to our forward-looking </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">guidance, and to identify operating trends in our business. We have excluded depreciation and amortization, and stock-based compensation expense because they are non-cash expenses that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented, and we have excluded impairment of goodwill, indefinite-lived intangible assets and long-lived assets to facilitate a more meaningful evaluation of our current operating performance and comparisons to our operating performance in other periods. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.</font></div><div><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investor Relations &#38; Media Inquiries </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Louise Wilkie&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;sangamo.com </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;sangamo.com </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-more-</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED CONSOLIDATED FINANCIAL DATA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited&#59; in thousands, except per share amounts)</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Operations Data&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,412&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,398&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,249&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,190&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,732&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,089&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,846&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,351&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,049&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,918&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,861&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,068&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,799&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,232&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and indefinite-lived intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,485&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,781&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,806&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,228&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,136&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,631&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,408)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,979)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,946)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,515&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,694&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,610&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,760&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,893)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,285)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,336)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,800)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,672&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,163)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,545)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,536)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income allocated to participating securities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,287&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-13.51pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) available to common stockholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,385&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,163)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,545)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,536)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-13.51pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-13.51pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per share</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,345&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,171&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,849&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,325&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,171&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,849&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selected Balance Sheet Data&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,201&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,002&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,263&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,320&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,134&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,887&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">###</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sgmo-20241112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c41ff5ca-2b50-4b76-8b33-b88e8ab04a52,g:83ec6252-6842-49ae-8980-2fdb865b3d01-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20241112" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20241112">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20241112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20241112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.sangamo.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sgmo-20241112_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c41ff5ca-2b50-4b76-8b33-b88e8ab04a52,g:83ec6252-6842-49ae-8980-2fdb865b3d01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a3baa1a0-e931-4e10-b5e6-de2f31910ce5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0238ecac-581c-44e0-8d10-ddf7ccce0752_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7505f2e2-e38b-4ccd-9727-abd2e68ff016_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0ef40103-ae08-46f5-a7b9-0075fe0493ea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_95d0ac00-504a-49a4-8e38-b618f3625c60_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_b1190c61-5534-458d-8bcb-56d3201bc952_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_db5a6732-9154-42a7-8455-b44c5bd21571_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2a626e57-49ca-4e14-9e2f-c5dcd33b82d6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_0b9e2044-586b-422a-9c67-408e7a62f05a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5f7a2d8f-520a-4318-a1c9-830048bd726e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f3d50d44-25b0-4477-8219-ce2321100ee4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_7ce73c01-8486-46b0-99f5-e3721ff68eac_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1c1546fd-3fae-4177-a361-0fc933db6e86_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9a5631d9-36f5-483b-ac26-887cb3bb4ed8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ae7deee6-67be-4aed-a0c8-30767771ce33_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3d15e236-bcc8-4ef6-83aa-328d2f35e142_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_82cd4746-beea-424d-baf7-d4da9b8b6c3b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_12f717f7-c941-4917-9a42-25c46aa5dfb9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d3e5121d-fe2c-49f1-a083-f97e60996232_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5e31755c-c589-4f0d-a25a-3683859f9310_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_1cf76f4e-166a-44c6-b447-bfbb89e2f22d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9b86be54-92b4-44f3-ac33-f5745f814260_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7f7b3121-f796-4778-a4a2-10777fc40ba4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sgmo-20241112_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c41ff5ca-2b50-4b76-8b33-b88e8ab04a52,g:83ec6252-6842-49ae-8980-2fdb865b3d01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CoverPage" xlink:type="simple" xlink:href="sgmo-20241112.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3db91615-0317-4295-be4c-b69bcb265c59" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_DocumentType_3db91615-0317-4295-be4c-b69bcb265c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_36c4d4cf-3091-4704-9373-4b1d2489f8de" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_DocumentPeriodEndDate_36c4d4cf-3091-4704-9373-4b1d2489f8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_92a6fe54-7aa0-4b53-957e-dc566ef956a0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityRegistrantName_92a6fe54-7aa0-4b53-957e-dc566ef956a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_38ace969-7473-4f27-b919-b35907ae3332" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_38ace969-7473-4f27-b919-b35907ae3332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9f38039c-6f04-4c5a-9ea9-6bb3b629efc8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityFileNumber_9f38039c-6f04-4c5a-9ea9-6bb3b629efc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d0d57afa-6e8d-417c-9c33-c6dcddcf1ff7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityTaxIdentificationNumber_d0d57afa-6e8d-417c-9c33-c6dcddcf1ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1ea821e4-21ae-4ee7-b4b6-2a148e27af14" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityAddressAddressLine1_1ea821e4-21ae-4ee7-b4b6-2a148e27af14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a6163daf-56b4-44de-8f73-97922e7d7eab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityAddressCityOrTown_a6163daf-56b4-44de-8f73-97922e7d7eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5bf2b6aa-0c62-43ee-b19c-f48e6b20bf1e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityAddressStateOrProvince_5bf2b6aa-0c62-43ee-b19c-f48e6b20bf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_542e28fe-ae4a-4071-97fc-50b85c12488d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityAddressPostalZipCode_542e28fe-ae4a-4071-97fc-50b85c12488d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ce592b42-638b-4f50-9821-08ec710e1278" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_CityAreaCode_ce592b42-638b-4f50-9821-08ec710e1278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4cb6d2dd-f396-44b4-bad7-8f55dce5d951" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_LocalPhoneNumber_4cb6d2dd-f396-44b4-bad7-8f55dce5d951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fbd266c9-fa24-4c81-87d2-d72f1e528642" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_WrittenCommunications_fbd266c9-fa24-4c81-87d2-d72f1e528642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a83be86d-1dd5-4a5a-a99b-5db2f6af7da1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_SolicitingMaterial_a83be86d-1dd5-4a5a-a99b-5db2f6af7da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_17e2bb71-7710-46bc-b0aa-595a4c0608e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_PreCommencementTenderOffer_17e2bb71-7710-46bc-b0aa-595a4c0608e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2263b71f-2880-4a23-adc6-380e70bee588" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2263b71f-2880-4a23-adc6-380e70bee588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_15b2313b-50d4-4f7d-9de4-99f3321d6783" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_Security12bTitle_15b2313b-50d4-4f7d-9de4-99f3321d6783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_177074fd-63b8-44ee-8bbc-56168f9a602d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_TradingSymbol_177074fd-63b8-44ee-8bbc-56168f9a602d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_54e712d2-b659-4739-a24c-4f02579efb98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_SecurityExchangeName_54e712d2-b659-4739-a24c-4f02579efb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d73fb163-be5c-4878-a9ca-df993a8c7306" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityEmergingGrowthCompany_d73fb163-be5c-4878-a9ca-df993a8c7306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c141b4b7-796e-45c6-a97c-06c4b26e5d41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_EntityCentralIndexKey_c141b4b7-796e-45c6-a97c-06c4b26e5d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_07023b98-203c-4c52-b58d-1da9cb909b41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_42c05bc9-e45e-49ba-85f2-b2b3b450c59c" xlink:to="loc_dei_AmendmentFlag_07023b98-203c-4c52-b58d-1da9cb909b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logoa.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logoa.gif
M1TE&.#EA@ -# 7   "'_"TY%5%-#05!%,BXP P$!   A^00      "P
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MQ"$' ;-E-79&/E157&_%98\ENQCT!2N% -OJI%]7 A]P.N3<.%XD-D($ 7F
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MB6 IYM;"23\1YPK1_\3.Z!,P')@DL&"$#P9ZCZ'=7*2R2BNOQ#++AQ K2"$
MK&*@! ]T<DFZD'#"*2WI6D- *@:B1&A*+36:2+>+[)P3(0;DY*T@"BCX (+Y
M?LRN+I1NFHLD,A55T[,SE^HQ._ZX@8$-'&@R2CV0G#OJNC9;U&V@*RBMCTRC
M)B!@ LQ".VZ^- W]PK*VRFP-)$<]BS2"&[J!P0H)HLHASSNK4HPQ!M@(H308
M+K!0.0)ZM*Q(,F]==*3["+SI. @Z"&$>':!9*QP!;Q"7.O32&B%8W!CR$L_=
M#J(H3!Q&&+<UG>ZK+%6GR*4).R#_I>ZF B+%3ZD'1O IA-JNT.H!IS2+M?^
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ME!:7&!@$/#MTVB8I((W;JH=$^  VJ(#P&YPQ.KX608PID9.^/$B(X#$^VRH
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M@*_I( Y:O!ZYOAI2LJ9 BN:2K,P8&-0Q)T;+0;0TJB)CO&KTH1O(1H880\R
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M_"D/0A0&&PE*4&$(8>=6#/*!*,I+1U.,5.> $S&0[ >5*;PI3G.*FC"^1H4
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M0%S/Q[F=H(3=4;"!_,R133S>CT#&60S6U6CD2AFF0:K%)^6(/V GT9!DFWI
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M8-/IC<(;$7BXF#+A%!0K+O7KIT9U@@3]7JM9 5LV;-BSY;5N?>0;0X5'KR"
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M(BZW@RQ"4 378 3RB"8Z3KXJ!S CH#+^[CK(YRC@R,)VT.=N( <7+Q0!( C
MC;?(:"LX)1AGCY^$* 5,X)/@<960#!Y!;\B0\'?FT5A^!P1.P"+J<F9D8A;3
M*RJ0Z"L@H&SRY#6M_W1=H*,O'M U?:,G2D"H$F.C+,L_4.;!8("]1"KC$D<2
M$\,_591$YNQ"P^<H\*PC0D*WP$I1HJHCMF_P--"[*F<F&\4!+BLL7"KA%NK\
MS&@\H<IT)NHHX*>FON_0C",DBDU+L^9"'K&LXF(D+F8WH0(KHV=H/L,9,4U
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M,5=BRS\49ZI&8[0 P X^:7<^\]T4MW&5\+ Z;P7T +("6XIRL'4QB?5@9("
M*[2A0Y4=N\6#)DO2X ,B9$B6SALL_[M=M)1D\BQ[G4U6M2+31B("T$A6"'!!
M#.,NJH?EW@9:695D2JI+6"2?E,M%HFID!V^ /W4&G0(!'+IY<U(GGR-1_9-%
M @73;DA!JE> *YBX/X*\;P)-B?A=W)9]\JTEV&^45^4&T&!NCB((.F#EQC-W
M9VJ@X?S*,CJ-:BG$,F,KQ#,M]0(#CS>)!,7-%N8]#<6+H]4N910SJ@81I[%S
M)K@B2@ P+7%/:4+5[,H&E>8B\DR\#;OY/ *C0F)C(!E82("Q#,LV-#,WB-3=
M>GW=DN=X)O>J<'*;8<P.#]L -Q<#/@IT7?S958("/J"D=&8NN&%._ON@\^HY
M0B "6FCR.O]#4*WRBH;\+Y#/V\F<+APSG>PB0J[ %F,-)7)@JZJ.?IWF,&HT
M;7CW.4Q640!3P)QQ.YV=(6Y<.KX3W (%_#Q4O)X#55J";\.&]2S,7@\\NJ,Z
M(E) L@=C K+8,!2P45FFK8!)+236DYLK=NSB BX  M8 ]QB "A(! H#7H[^6
M)"3 0=];T@&1@">T),*2X*MD&?.(S4P<N&S&;9*&(8#X<<#%PD!$:UET2L8'
MC#]@1!*P918VT!5$)_SE=E( "XC%Q\H5"6%8<1-+6JX9Q 5GWE?$C]QBM\OH
M]6 " SQ@_UCZV0U.F1JH7RZ" F!T>DK"O(E@[.ARI:LJ-JU$@53_ L\LVIC]
MY*L[\)ZW,SH6"@88I;]4[D6V^ (0H!Z&LN") N'TY ,P1<&_S];:5)_XR?82
MD_D6.6,6(&<,=9@H7\QUL%.)0ZT>2@*HF"+JI/*[K@"CK/!^)+A,Y"SD!47J
M2/E+!2WHP +JX75RAM"L<A.GD0'L99XNA0#A4OWTE".@(1$Z8,Z^X^XWC($:
M9Y8D",8R@\P<):GG+@-_37F1))P+QC>5U"F3#0?#CZ@ @D"X&_YN?/G"[P8"
M.@ :.GP(,2*1A@P *%#0L 0"A \,>GQ0 &%"?B"EL('((&40*U\*C/18P&/!
M+S<>1"AP 0$"#_-2 F" ,061%9=6]$O0_R_I"GG]EO:[I)2ITP1&Y1'=8(=*
M"HH5M^*00!,D 8,T:7XTR*_@#0P:'GJ+"#>NW+ETZ]J]BS>O7 H*&!"YJ& B
M5P8EV.B$4/9@!!@(1K!)6?&GX!21'V*T"!$C4,R7.UO<VA"T0PH-_S9,@\!@
M1Q@1#$8X>"-AV-@=OSP882$'@(D5V?AK7=OCE]=D;=9T< -'9-Z\*8;6Z_QA
MY(H8+S.@$R)UR,0P#2+@US(F @T^(6I(7?NUO[*U:1:(*4%$^8:7H>/5#. *
MA!OO!\*&W5%'X7R!  0Y5$8: !_XL]$#!+P7$DP=$4! 0HR-0 $#?$7'&681
M5?>0:*!5)QAI%?]I  %Z$3R D' 3VM2108E4)AT#]4A04SBOF<4=2!T5 $,B
M"?I5&G65B7:7 DA*9YE@#.AW@T$$V/3?CF5YAT %\S5T'G^*$4A30@6PZ)T'
M\]67UX@_K8$>0;"]1Q-BKA&HFX=ZH7E9"3 ,1^:;-+TF9@&.14::9B7L!R-Q
M9 GGT8HA(2??3Y41080>&RC55%*:*F544E*I@113'*R 16F25K0&!&H]T)%L
MPEW))X$(?%"1DS_9AVNNNNZ:JV=_8>1-AH0% 0,W!L748ED%>K#&K?6]Y="2
MM[X%;7T@>I:D=2(@4%" JAT;EFQEO183!"F(QD %#OQWP4?CUO1M!%?_1/:6
M8+S22*.=7%7 #0P.\+-CE&7%E-9K#Q8P7KXIX;!13;#]%J9'"[2D4 7U2<LK
M1 E*FMVQPA%'4S@%^'>#!'4^QX (%J@E\GL&82 <P"PN-IY#]M*%\5S>O*4
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MI5,"3L,2.V>GX,@G4TIC9K0E9:D=X)%M?!(<;B2%]M%Q0W:$._(>@"DG"(0
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MAP_H +((NBK[P-72+K+ D0Q<M 7(1-6ZPVD*#7ZP@F[PP*20D[1@B'P"KXT
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M#@0%/@.##"(P@3J0CR[(!P[H!PZ0T0F[/N>CL'<]*0,ID.FCT1RJO@K;  X
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M /\;<J"2; 64/I_=K!"?&1%Z3N1-.:B RCY@W ]HX+C&K6T:^N>7!NXN(D3
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MS1% 2BG&>?"&1"I$?A'F<OY%A.@,B02)CE@'&]!'C]Z8?J9JL1KKL2+KF#(
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M30S0[!8(3Q;#3T*BPV)/(31C?Z $4+JM>FP.9GJE9_KC:_2@.^S-?18"04!
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M!A^_#]-<A9BPT!OM0#UD[XPZR>]B8RH9 \[,)N1$(I=FPVI.XVA(0#.Z8,[
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AW=5?'=9C7=9GG=9KW=9O'==S7==WG==[W==_/7 " @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46397417234320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">501 Canal Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Richmond<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MC@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( "B
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M"@.4;ZH5E=>2BBTGW='K3.\?)H]:1NO<2KGW\$JV''..?[3\ 5!+ P04
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MUDX:?^:+X3]>?P%02P$"% ,4    "  H@&Q9!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "B ;%EO
MMZV_[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( "B ;%F97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ *(!L65>BCT%-!
M@A   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( "B ;%F?H!OPL0(  .(,   -              "  9 ,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ *(!L69>*NQS     $P(   L
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64$L%!@     )  D /@(  .@3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sgmo-20241112.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="sgmo-20241112.htm">sgmo-20241112.htm</File>
    <File>sgmo-20241112.xsd</File>
    <File>sgmo-20241112_lab.xml</File>
    <File>sgmo-20241112_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sgmo-20241112.htm": {
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20241112",
   "dts": {
    "inline": {
     "local": [
      "sgmo-20241112.htm"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20241112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20241112_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20241112_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.sangamo.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20241112.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sgmo-20241112.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.sangamo.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-047099-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-047099-xbrl.zip
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M:IW #F,[+% "1!@@ SB:IB]G0U!AI#=I\-_@:2"B,T)!,G)F^2"W'HJE',/
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M*L6F'R@KE<(0)0)Q02;*!'D$:Y6^GAH^0<H2)U]A+P\\KMLB"P*509=V6*6
MK%B]R/H=WPBOMJU.\V]SJQ@Q=\DBC)1VZI7._&-%IQ3C#6H=6$(.6'K]4 >I
M!9$KT;\]?6Y A2!S8^HVG=6.,/-.M762@;*H#BDBS50RI:/<F+9X+D9;HO1R
M;\ZIO6JEV@:U5P&]5^U P)MAF:H>&9A+&[\M3)C23]Z,VZM\<X* ;@JDC 2'
M.""22996[U"0)LF!(:?6"4PW#%FE;&\Y+@.)2P)]5,-Z-P+&8]I_R3I-6!R-
M4+1$V<^Y_0P0<&5N>Z+>WJRY9AH'Z_5\UR=MC9C;ITE[A*C%3V=[DQ V:=3+
MLWAI2R%Z&*MD')\T[8"F23#7.SBP:N S'$+L]3=+K(SCK:3H@DGIXFS09U_8
M:+AY>^'>]!)>I?M!OID-//N[@L5B=&HV7%[E-EQ^ ZZ4"F);"B+=B3NW/4NF
MY?5L<];"Q-C\U@"Y),VU=!?7S<75D^V[+7'PF/Y2I>(Q[?["CE!F&G9H1QL"
MP\2DU#]ZSW/[Z:BPM*#:F-89\:.Q<%V/I\7PDHG;<L%BJK^CK8/HUX^5$XH@
M0B[TA;S^#H2F4[7 [IGMK-^H J,S8=S#HQ<FV 6 R62*MG [[.E5MX?\3[8(
MPNC_$;Z#1<8A#Y-O2XBB#_[?Q;7ZL%CR9R4YV9M;#+@HJ8>CF'8=,R5/NQ*Z
M7I2&?/020&)NLE=L4JNT+25=$8]!BS#?YQX=+:&XK] EH7GX2J?.(0KT*-WN
M02B8ZYZST'>E?@Z<V(AC*P,K'OR#E"&-N!S-9>/H_&OWWP/Y%B)[R^T,V]54
MZ:X7G>4TL>!_3*_3Z6WO ^@;["9"<<Q*T\D^]'S-.7>60;H;/]F CSX,:B&L
M!\# Z?$"'E;3=&<K=JKH78BD&B+04J"B>KU_)?L:[WQY[V-^]N:V=WKXZ=,G
M6ZNI$:5L<ZE/X'8,/T]AI8P* 7T/CP[KA^CH]%D8"CQR"ATEHT/@S[[T1S%0
M6!<L(ECBP=7G;Z1$$VU$2FC"?6S=*BJA,E&Y/4NJRZEXD"5M.C8U96"[U@]T
M3LBIQ&H2-3?G-N7H%IBDB9K2]6BWG&GN<(D4J&#K],8+ TVP1C']"S8)WY9N
MML,V+(*MIW0S%CZY.!%:-(D:^>/KJUX25$=<I.V#!$X;'H$9NO"L?KV*PXF8
M4'D+2]@0()C6(3Q=++5_D?R.QIS&9\,AN/X(X-*[VYJ+GK9B>E/RPH,4I* S
M4H"2+[X(I'E0LFC&RUFH8'0(P V/ 7%VLLL;WHEGSF4J49^4HWL/@\RK!/>
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M#0$6"\\M;4ZG_F]EG:-?C<7"@FO]AJESA;L[UB=.*1>KOFI</3J<.( %8>;
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M6 %P(K79!+"'PB?;#M"*L3K8GZ8>!IA8-.VK)X7?0$_#O'):'!+?G7=+$J]
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MB8H)TO*].&")=-\Z?MM8?%IYIIM#K#S$&/AB"R;_#LHW&=H'65H L9P-0>^
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M.<]GFYMVIUI=WS+O65RO*=S8<T-\Q:,DGM=!?AG0/V7%OKWI]I0R7MAKGD)
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MWE^" G$:9/./99<,3DN! 7C'>*1&(M0[CV&Z21N@XSCJQ"$9_TXF)43#T]+
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M<S\![LU=]O ?^3VM)W[]8/%PQ\:,PHH9RK_?;+/GI[<J?.I75$(/S60WBMS
MV]B)V-N7S>.^0_9E.48?)]Y[E\^W@%19E%&O?=7OHX\F^J/S]>O5MR^_??R?
MEUQC_I[5\3WCOO.F2)V5>K?&Z*5'Y7:+A;T B*U-%(TBEMX,_<G>1.U-U$]C
MHO0Y\7=KH]X,FWHDIHRC_Z9!5@VN?S?]"'W)2Z/5;TL)$NG*X791TJVRX)Q(
MS)=8K)]T;Z?LLW "_PWE*&K]/U!+ P04    "  H@&Q9T0-,)60"   #!P
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MVUVK2G.>WRW*XO$\UV8JB!0""0A,2A"@!D$@F8F!-M@2E"*H#)N63U_QJ5F
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M<V*:X+9GB>?2%MH!YYSM (RO3F(0)V+JG.Q.YTE@\[:LX+>KM8>\L(F;@MM
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M@:.]^Q^ZE^[!^*.]_P-02P$"% ,4    "  H@&Q9,7/=9]\P   IY@$ %0
M            @ $     97AH:6)I="TY.3$Q,3$R,C0N:'1M4$L! A0#%
M  @ *(!L693AM*X)$   ?8,  !$              ( !$C$  '-G;6\M,C R
M-#$Q,3(N:'1M4$L! A0#%     @ *(!L6=$#3"5D @   P<  !$
M     ( !2D$  '-G;6\M,C R-#$Q,3(N>'-D4$L! A0#%     @ *(!L66<S
M#]PP"@  >%4  !4              ( !W4,  '-G;6\M,C R-#$Q,3)?;&%B
M+GAM;%!+ 0(4 Q0    ( "B ;%GZ[8E>KP8  .@P   5              "
M 4!.  !S9VUO+3(P,C0Q,3$R7W!R92YX;6Q02P4&      4 !0!' 0  (E4
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>sgmo-20241112_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sgmo-20241112.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001001233</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30171</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">501 Canal Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Richmond</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94804</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">970-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
